Format

Send to

Choose Destination
Acad Radiol. 2017 Aug;24(8):930-940. doi: 10.1016/j.acra.2016.09.003. Epub 2016 Oct 18.

A Study of the Feasibility of FDG-PET/CT to Systematically Detect and Quantify Differential Metabolic Effects of Chronic Tobacco Use in Organs of the Whole Body-A Prospective Pilot Study.

Author information

1
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104. Electronic address: Drew.Torigian@uphs.upenn.edu.
2
Department of Emergency Medicine, Division of Occupational Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
3
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104.
4
Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
5
Penn Superfund and Research Training Program (SRP) and Center of Excellence in Environmental Toxicology, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania.

Abstract

RATIONALE AND OBJECTIVES:

The aim of this study was to assess the feasibility of 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) to systematically detect and quantify differential effects of chronic tobacco use in organs of the whole body.

MATERIALS AND METHODS:

Twenty healthy male subjects (10 nonsmokers and 10 chronic heavy smokers) were enrolled. Subjects underwent whole-body FDG-PET/CT, diagnostic unenhanced chest CT, mini-mental state examination, urine testing for oxidative stress, and serum testing. The organs of interest (thyroid, skin, skeletal muscle, aorta, heart, lung, adipose tissue, liver, spleen, brain, lumbar spinal bone marrow, and testis) were analyzed on FDG-PET/CT images to determine their metabolic activities using standardized uptake value (SUV) or metabolic volumetric product (MVP). Measurements were compared between subject groups using two-sample t tests or Wilcoxon rank-sum tests as determined by tests for normality. Correlational analyses were also performed.

RESULTS:

FDG-PET/CT revealed significantly decreased metabolic activity of lumbar spinal bone marrow (MVPmean: 29.8 ± 9.7 cc vs 40.8 ± 11.6 cc, P = 0.03) and liver (SUVmean: 1.8 ± 0.2 vs 2.0 ± 0.2, P = 0.049) and increased metabolic activity of visceral adipose tissue (SUVmean: 0.35 ± 0.10 vs 0.26 ± 0.06, P = 0.02) in chronic smokers compared to nonsmokers. Normalized visceral adipose tissue volume was also significantly decreased (P = 0.04) in chronic smokers. There were no statistically significant differences in the metabolic activity of other assessed organs.

CONCLUSIONS:

Subclinical organ effects of chronic tobacco use are detectable and quantifiable on FDG-PET/CT. FDG-PET/CT may, therefore, play a major role in the study of systemic toxic effects of tobacco use in organs of the whole body for clinical or research purposes.

KEYWORDS:

CT; Fluorodeoxyglucose (FDG); inflammation; metabolism; positron emission tomography/computed tomography (PET/CT); smoking; tobacco use

PMID:
27769824
PMCID:
PMC5793901
DOI:
10.1016/j.acra.2016.09.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center